Lantus solostar (insulin glargine): Uses, Dosage & Side Effects

What it's for (Indications)

Insulin glargine is a long-acting human insulin analog indicated for the improvement of glycemic control in adults and pediatric patients 6 years of age and older with type 1 diabetes mellitus, and in adults with type 2 diabetes mellitus.
It is designed to provide a continuous, basal insulin supply, helping to maintain stable blood glucose levels throughout the day and night.
This medication is typically used as part of a comprehensive diabetes management plan that includes diet, exercise, and often, other antidiabetic agents.
Its primary role is to replace the body's natural basal insulin production, which is either absent (Type 1) or insufficient (Type 2), thereby preventing excessive hepatic glucose output and promoting glucose uptake by peripheral tissues.
This contributes significantly to overall metabolic control and reduction of long-term diabetes complications, aiming to achieve and maintain target glycemic goals.

Dosage Information

Type	Guideline
Standard	The dosage of insulin glargine must be individualized based on the patient's metabolic needs, blood glucose monitoring results, and glycemic goals. It is administered subcutaneously once daily at the same time each day. For patients with type 1 diabetes, the typical initial dose is approximately one-third to one-half of the total daily insulin requirement, often combined with short-acting or rapid-acting insulin given before meals. In patients with type 2 diabetes, a common starting dose is 0.2 units/kg or 10 units once daily, with subsequent titration based on glycemic response and regular blood glucose measurements. Dose adjustments may be necessary in patients with renal or hepatic impairment, during periods of illness, changes in diet, exercise regimens, or with concomitant use of other medications that affect glucose metabolism. Regular self-monitoring of blood glucose is crucial to guide dose adjustments and prevent episodes of hypoglycemia or hyperglycemia. Patients should be educated on proper injection technique and rotation of injection sites to minimize the risk of lipodystrophy and ensure consistent absorption.

Type

Guideline

Standard

The dosage of insulin glargine must be individualized based on the patient's metabolic needs, blood glucose monitoring results, and glycemic goals. It is administered subcutaneously once daily at the same time each day. For patients with type 1 diabetes, the typical initial dose is approximately one-third to one-half of the total daily insulin requirement, often combined with short-acting or rapid-acting insulin given before meals. In patients with type 2 diabetes, a common starting dose is 0.2 units/kg or 10 units once daily, with subsequent titration based on glycemic response and regular blood glucose measurements. Dose adjustments may be necessary in patients with renal or hepatic impairment, during periods of illness, changes in diet, exercise regimens, or with concomitant use of other medications that affect glucose metabolism. Regular self-monitoring of blood glucose is crucial to guide dose adjustments and prevent episodes of hypoglycemia or hyperglycemia. Patients should be educated on proper injection technique and rotation of injection sites to minimize the risk of lipodystrophy and ensure consistent absorption.

Safety & Warnings

Common Side Effects

The most frequently reported and clinically significant adverse reaction associated with insulin glargine therapy is hypoglycemia.
This can range from mild episodes managed by carbohydrate intake to severe events requiring assistance, potentially leading to loss of consciousness, seizures, or permanent neurological damage.
Other common side effects include various injection site reactions such as pain, redness, itching, urticaria, or inflammation, which are usually mild and transient.
Lipodystrophy (lipoatrophy or lipohypertrophy) may occur at the injection sites if sites are not rotated consistently.
Less common but serious side effects include hypersensitivity reactions, including rare cases of generalized allergic reactions and anaphylaxis, which require immediate medical attention.
Weight gain, peripheral edema, and hypokalemia have also been reported.
Patients should be counseled on recognizing the signs and symptoms of hypoglycemia and appropriate management strategies, as well as the paramount importance of regular blood glucose monitoring to mitigate these risks.

Serious Warnings

Black Box Warning: Serious Warnings Insulin glargine does not carry an FDA-mandated Black Box Warning. However, healthcare professionals and patients should be acutely aware of several serious risks associated with its use. The most critical serious risk is **hypoglycemia**, which can be profound and life-threatening, potentially leading to coma, seizures, and permanent neurological damage. Patients must be educated on the symptoms, monitoring, and immediate management of hypoglycemia. Close monitoring of blood glucose is essential to minimize this risk. Another significant concern is the potential for **medication errors**, particularly accidental mix-ups between different insulin products or concentrations, or sharing of insulin pens between patients, which can lead to serious infections or inaccurate dosing. Strict adherence to proper dispensing, administration techniques, and patient education is paramount. Furthermore, concomitant use of insulin glargine with **thiazolidinediones (TZDs)**, like pioglitazone or rosiglitazone, may lead to fluid retention and exacerbate or cause heart failure, even in patients without pre-existing cardiac dysfunction. Patients should be observed for signs and symptoms of heart failure, and appropriate medical management should be initiated if it develops. Any unexplained weight gain or new or worsening shortness of breath should prompt immediate medical evaluation. Patients should always verify the insulin product and dose before injection.
Several important warnings and precautions are associated with insulin glargine use.
The most critical is the risk of hypoglycemia, which can be severe and life-threatening; patients must be carefully monitored, and dosage adjustments should be made cautiously based on blood glucose readings.
Hypersensitivity reactions, including generalized allergic reactions and anaphylaxis, may occur and warrant immediate medical intervention.
Fluid retention, with or without heart failure, can develop with the concomitant use of insulin glargine and thiazolidinediones (TZDs), particularly in patients with pre-existing heart failure or renal impairment; close monitoring for signs and symptoms of heart failure is advised.
Insulin glargine pens and syringes are strictly for single-patient use only to prevent the transmission of blood-borne pathogens.
Hypokalemia, although rare, can occur and requires monitoring, especially in patients at risk or on potassium-lowering medications.
Careful consideration should be given to dose adjustments in patients with renal or hepatic impairment due to altered insulin metabolism.
Patients should be advised against sharing needles or pens and to seek immediate medical attention for any severe reactions or unexpected symptoms.

How it Works (Mechanism of Action)

Insulin glargine is a recombinant human insulin analog engineered to have a prolonged duration of action. After subcutaneous injection, its acidic pH causes it to form a soluble precipitate in the neutral pH of the subcutaneous tissue. This precipitate slowly and continuously releases small amounts of insulin glargine, resulting in a relatively constant concentration-time profile over 24 hours with no pronounced peak. Once absorbed into the bloodstream, insulin glargine is metabolized into active metabolites (M1 and M2) that retain insulin activity. These metabolites, like endogenous insulin, primarily function by binding to insulin receptors on target cells, including muscle and adipose tissue, thereby enhancing glucose uptake and utilization. Concurrently, insulin glargine inhibits hepatic glucose production, reduces lipolysis in adipocytes, and decreases proteolysis, all contributing to lowering blood glucose levels. Its sustained action provides essential basal insulin coverage, crucial for maintaining glycemic homeostasis between meals and overnight, mirroring the body's natural basal insulin secretion.